Posters

Intralenticular foreign body

Poster Details

First Author: M.Stamenkovic SERBIA

Co Author(s):    V. Jakšic   Z. Zikic   A. Bajic   B. Vukadinovic   N. Nikitovic   M. Novakovic     

Abstract Details

Purpose:

Evaluation and treatment of patients with traumatic cataract and intraocular foreign body located in the lens.

Setting:

Eye Clinic, University Medical Center ″Zvezdara″, Belgrade, Serbia

Methods:

We evaluated two patients with intralenticular foreign bodies and traumatic cataracts treated in Eye Clinic University Medical Center ″Zvezdara″, Belgrade.

Results:

Of all open globe injuries, intraocular foreign bodies (IOFB) are present in 19 to 43% of cases, but only 7-10% are located in the lens. Patients with IOFBs are overwhelmingly male (>95%) with mean age at presentation between 20 and 41 years. A 24-year-old male patient presented with a history of trauma to the left eye while hammering metal. Patient`s initial best corrected visual acuity (BCVA) on injuried eye was light perception (LP). Further examination revealed penetrating corneal wound, traumatic cataract and metallic IOFB located in the lens. First, corneal wound was sutured, then IOFB was removed followed by cataract extraction by phacoemulsification and implantation of PC IOL. The patient was discharged with visual acuity (VA) 0.7. The second patient also had a penetrating eye injury with metallic intralenticular foreign body. Slit-lamp examination showed full-thickness corneal laceration and total lens opacity. Visual acuity on admission was found to be also light perception(LP). After primary repair of entry wound, combined surgery with IOFB removal, phacoemulsification and PC IOL implantation were performed.

Conclusions:

Conclusion Traumatic cataracts after penetrating injuries with IOFB located in the lens can be successfully treated with standard phacoemulsification followed by implantation of PC IOL. However, visual outcome depends on several factors which include size, location, material, time of surgical repair and removal of IOFB, as well as development of endophthalmitis. Financial disclosure Authors declare no financial interest.

Financial Disclosure:

gains financially from competing product or procedure, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, is employed by a competing company, has significant investment interest in a company producing, developing or supplying product or procedure presented